News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle Biotech Acucela Inc. Seeks $125 Million IPO in Japan to Develop Eye Drugs



12/18/2013 6:26:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Seattle-based Acucela is looking to raise as much as $125 million in an initial public offering to support its development of treatments against eye diseases.

Acucela today filed its IPO prospectus with the Securities and Exchange Commission, outlining plans to go public on the Tokyo Stock Exchange. It’s a logical place for Acucela to turn for investment capital, given that founder and CEO Ryo Kubota, 46, is a native of Japan. An ophthalmologist formerly with the University of Washington, Kubota has retained strong connections in his native country, and he has built Acucela with support of a key partner in Japan-based Otsuka Pharmaceuticals.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy
Read at Seattle Times
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES